Literature DB >> 30505233

False-positive prostate cancer bone metastases on magnetic resonance imaging correctly classified on gallium-68-prostate-specific membrane antigen positron emission tomography computed tomography.

Sofiullah Olayinka Abubakar1, Yaw Ampem Amoako1, Naima Tag1, Tessa Kotze1.   

Abstract

Imaging in prostate cancer is important in defining the local extent of disease, nodal involvement, and identifying metastases. Bone scan is the most commonly used modality for identification of bone metastasis in prostate cancer despite its reported low sensitivity and specificity compared to magnetic resonance imaging (MRI) which is the imaging gold standard for bone metastasis. Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography (68Ga PSMA PET-CT) imaging is a relatively new addition to the imaging modalities in prostate cancer. This is a report of a patient with high-risk prostate cancer with features consistent with skeletal metastases on MRI but negative for skeletal metastases on bone scan and 68Ga PSMA PET CT. Histology confirmed the absence of skeletal metastases.

Entities:  

Keywords:  68Gallium prostate-specific membrane antigen positron emission tomography-computed tomography; bone metastasis; magnetic resonance imaging; prostate cancer

Year:  2018        PMID: 30505233      PMCID: PMC6216739          DOI: 10.4103/wjnm.WJNM_89_17

Source DB:  PubMed          Journal:  World J Nucl Med        ISSN: 1450-1147


  9 in total

Review 1.  Gallium-68 Prostate-Specific Membrane Antigen PET Imaging.

Authors:  Michael S Hofman; Amir Iravani
Journal:  PET Clin       Date:  2017-02-01

2.  Guideline for the management of clinically localized prostate cancer: 2007 update.

Authors:  Ian Thompson; James Brantley Thrasher; Gunnar Aus; Arthur L Burnett; Edith D Canby-Hagino; Michael S Cookson; Anthony V D'Amico; Roger R Dmochowski; David T Eton; Jeffrey D Forman; S Larry Goldenberg; Javier Hernandez; Celestia S Higano; Stephen R Kraus; Judd W Moul; Catherine M Tangen
Journal:  J Urol       Date:  2007-06       Impact factor: 7.450

Review 3.  EAU guidelines on prostate cancer.

Authors:  Axel Heidenreich; Gunnar Aus; Michel Bolla; Steven Joniau; Vsevolod B Matveev; Hans Peter Schmid; Filliberto Zattoni
Journal:  Eur Urol       Date:  2007-09-19       Impact factor: 20.096

4.  68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.

Authors:  Wolfgang P Fendler; Matthias Eiber; Mohsen Beheshti; Jamshed Bomanji; Francesco Ceci; Steven Cho; Frederik Giesel; Uwe Haberkorn; Thomas A Hope; Klaus Kopka; Bernd J Krause; Felix M Mottaghy; Heiko Schöder; John Sunderland; Simon Wan; Hans-Jürgen Wester; Stefano Fanti; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06       Impact factor: 9.236

Review 5.  Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis.

Authors:  Guohua Shen; Houfu Deng; Shuang Hu; Zhiyun Jia
Journal:  Skeletal Radiol       Date:  2014-05-20       Impact factor: 2.199

Review 6.  Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.

Authors:  Clemens Kratochwil; Ali Afshar-Oromieh; Klaus Kopka; Uwe Haberkorn; Frederik L Giesel
Journal:  Semin Nucl Med       Date:  2016-09       Impact factor: 4.446

Review 7.  Prostate cancer.

Authors:  Jan-Erik Damber; Gunnar Aus
Journal:  Lancet       Date:  2008-05-17       Impact factor: 79.321

8.  Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies.

Authors:  Frédéric E Lecouvet; Daphné Geukens; Annabelle Stainier; François Jamar; Jacques Jamart; Bertrand Janne d'Othée; Patrick Therasse; Bruno Vande Berg; Bertrand Tombal
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544

Review 9.  Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases.

Authors:  S D Sweat; A Pacelli; G P Murphy; D G Bostwick
Journal:  Urology       Date:  1998-10       Impact factor: 2.649

  9 in total
  1 in total

1.  Significant Diagnostic Value of Free-Serum PSA (FPSA)/Prostate-Specific Antigen Density (PSAD) and (F/T)/PSAD for Prostate Cancer of the Chinese Population in a Single Institution.

Authors:  Li-Bin Nan; Xiao-Tao Yin; Jiang-Ping Gao
Journal:  Med Sci Monit       Date:  2019-11-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.